shutterstock_1425438833_ii-studio
II.studio / Shutterstock.com
22 September 2022AmericasStaff Writer

Swiss pharma company reveals SCOTUS appeal plans

Federal Circuit denies petition to rehear dispute over multiple sclerosis medicine | Company will petition highest court over invalidity ruling.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
20 September 2022   Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition
Big Pharma
29 September 2022   Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.
Americas
6 October 2022   HEC claims the delay would buy Novartis months of “unjustified monopoly profits” | Response says the Swiss big pharma company makes $3.8m a day from multiple sclerosis drug at issue.

More on this story

Big Pharma
20 September 2022   Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition
Big Pharma
29 September 2022   Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.
Americas
6 October 2022   HEC claims the delay would buy Novartis months of “unjustified monopoly profits” | Response says the Swiss big pharma company makes $3.8m a day from multiple sclerosis drug at issue.

More on this story

Big Pharma
20 September 2022   Authority carries out dawn raid at Novartis’ premises | Probe focuses on the alleged unlawful use of a skincare patent to bar competition
Big Pharma
29 September 2022   Bid to stay invalidity decision pending a SCOTUS appeal fails | Patent covers a multiple sclerosis drug | Company could take $300m hit if generics are launched.
Americas
6 October 2022   HEC claims the delay would buy Novartis months of “unjustified monopoly profits” | Response says the Swiss big pharma company makes $3.8m a day from multiple sclerosis drug at issue.